All In Biotech

Drug Trial Radar · NCT05765812

A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

May 15, 2023

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Debiopharm International SAIndustry
Sponsor type
Industry
First posted
Mar 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm. The primary purpose of Phase 1 (Dose expansion) of the study is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development. The Phase 2 will start once the RD Phase 1 has been defined. The primary objective of Phase 2 is to assess the efficacy of zedoresertib at the RD for further development in combination with TMZ, compared to the standard of care (SOC) in adult participants with GBM.

Conditions

  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
  • Astrocytoma, Grade III

Interventions

  • ZedoresertibDrug

    Administered as capsules.

  • TemozolomideDrug

    Administered as capsules.

  • RadiotherapyRadiation

    Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose Escalation): Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Phase 1: Arm A: Cycle 1 (Cycle=28 days); Arms B and C: Up to approximately 1.8 months
  2. Phase 1 (Dose Escalation): Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE)Time frame: Up to 30 days after the end of treatment (Arm A: Up to approximately 26 months and Arms B and C: Up to approximately 3.5 months)
  3. Phase 1 (Dose Escalation): Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, Electrocardiogram (ECG), and Echocardiogram (ECHO) ParametersTime frame: Up to 30 days after the end of treatment (Arm A: Up to approximately 26 months and Arms B and C: Up to approximately 3.5 months)
  4. Phase 1 (Dose Escalation): Change From Baseline in Karnofsky Performance Status (KPS) ScoreTime frame: Until disease progression or end of study (approximately 66 months)
  5. Phase 1 (Dose Expansion): Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE)Time frame: Up to approximately 26 months
  6. Phase 1 (Dose Expansion): Change from Baseline in Tumor Size Assessed by Objective Response (OR) as per Response Assessment in Neuro-oncology (RANO) CriteriaTime frame: From the start of study treatment until disease progression or end of study (up to approximately 66 months)
  7. Phase 1 (Dose Expansion): Plasma Concentration of Zedoresertib and its MetaboliteTime frame: Predose and at multiple timepoints up to 6 hours post dose up to Day 15 of Cycle 1 (Cycle=28 days)
  8. Phase 1 (Dose Expansion): Pharmacodynamic(s) PDy, Change from baseline in Phosphorylated Cell Division Cycle (pCDC2)Time frame: Predose and 4 to 6 hours post dose on Day 10 of Cycle 1 (Cycle=28 days)
  9. Phase 2: Overall Survival (OS)Time frame: From the start of study treatment until death from any cause or end of study (up to approximately 66 months)

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • New York University Langone Medical Center

    New York, New York · Recruiting

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Baylor Scott & White Research Institute

    Dallas, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Spain · Recruiting

  • Clinica Universidad de Navarra (CUN)

    Madrid, Spain · Recruiting

  • South Texas Accelerated Research Therapeutics (START)

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra (CUN)

    Pamplona, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

  • Universitaetsspital Zuerich

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.